Familial colorectal cancer risk: ESMO clinical recommendations

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Vasen, H F A ^a,b   van der Meulen de Jong, A E ^b   de Vos tot Nederveen Cappel, W H ^b   Oliveira, J ^c  

^a Foundation for the Detection of Hereditary Tumours   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DNA GLYCOSYLASE MUTY; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1;

ADENOMATOUS POLYP; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CARDIOVASCULAR SYMPTOM; CHEMOPROPHYLAXIS; COLON RESECTION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DISEASE SURVEILLANCE; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GENE EXPRESSION; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; RISK ASSESSMENT;

COLORECTAL NEOPLASMS; EUROPE; HEALTH PLANNING GUIDELINES; HUMANS; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 66549118536     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp127     Document Type: Article

References (13)

1. Vasen HFA, Möslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-362.
2. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition - Update of ICG-HNPCC.INSIGHT mutation database. Dis Markers 2004; 20: 269-276.
3. Guillem JG, Wood WC, Moley JF et al. ASCO/SSO review of current role of riskreducing surgery in less common hereditary cancer syndromes. J Clin Oncol 2006; 24: 4642-4660.
4. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-425.
5. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
6. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996; 69: 38-43.
7. Jarvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834.
8. Bisgaard ML, Fenger K, Bulow S et al. Familial adenomatous polyposis (FAP): Frequency, penetrance and mutation rate. Hum Mutat 1994; 3: 121-125.
9. Aretz S, Uhlhaas S, Caspari R et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 2004; 12: 52-58.
10. Sieber OM, Lipton L, Crabtree M et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348(9): 791-799.
11. Gismondi V, Meta M, Bonelli L et al. Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer 2004; 109: 680-4.
12. Nielsen M, Franken PF, Reinards TH et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 2005: 42 e54.
13. Vasen HF, Möslein G, Alonso A et al. Guidelines for the clinical management of familial adenomatous polyposis. Gut 2008; 57: 704-713.